Alliance Pharma (LSE:APH) Buyback Yield % : -0.04 (As of May. 16, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Alliance Pharma's current buyback yield was -0.04%.

Alliance Pharma Buyback Yield % Historical Data

The historical data trend for Alliance Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Buyback Yield % Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Buyback Yield %

Get a 7-Day Free Trial

-10.03

-1.01

-0.35

-0.13

-0.12

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Buyback Yield %	Get a 7-Day Free Trial															-0.13	-0.13	-0.09	-0.04	-0.03

Competitive Comparison of Alliance Pharma's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alliance Pharma's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Buyback Yield % falls into.

Alliance Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Alliance Pharma's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0.341)	/	286.19735
	=	-0.12%

Alliance Pharma's annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0.034)	*	2	/	269.264775
	=	-0.03%

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Jun. 2023) data.

Alliance Pharma Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).